All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, What is the impact of dexamethasone dose strength on outcomes in newly diagnosed multiple myeloma?
What is the impact of dexamethasone dose strength on outcomes in NDMM?
Banerjee discusses the toxicity profile of dexamethasone in patients with newly diagnosed multiple myeloma treated with a standard dose of ~40 mg weekly. He then explores the impact of reducing dexamethasone dose strength on incidence and patient outcomes, highlighting both the frequency of adverse events and differences in efficacy outcomes. He concludes by explaining the implications of this data on future dexamethasone use and how to determine the optimal initial dose strength.
PERSEUS: Primary efficacy and safety results
We summarize a presentation by Sonneveld from ASH 2023 on a primary analysis from the randomized phase III PERSEUS trial investigating daratumumab and VRd therapy for the treatment of transplant-eligible...
Initial results of daratumumab + lenalidomide in frail patients: The IFM 2017-03 trial
The Multiple Myeloma Hub summarizes data from the IFM 2017-03 trial, presented at ASH 2022, exploring the efficacy and safety of dexamethasone alongside...
Subscribe to get the best content related to multiple myeloma delivered to your inbox